Benzinga | Mar 30, 2021 08:37AM EDT

BioSig Awarded US Patent Claims For Noise-Filtering Methods For Its Signal Processing Technology

Westport, CT, March 30, 2021 (GLOBE NEWSWIRE) --

* Claims address computer-implemented systems and methods for filtering noise from input cardiac signals using its PURE EP(tm) technology designed to elevate treatments for cardiac arrhythmias

* Atrial fibrillation is the most common arrhythmia type, affecting over 6 million people in the U.S. and causing more than 750,000 hospitalizations each year

* BioSig now has 34 issued or allowed worldwide patents covering its advanced PURE EP(tm) technology

BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the U.S. Patent Office had allowed a utility patent covering its PURE EP(tm) noise-filtering technology. The recently allowed patent application number 17/082,564 entitled "SYSTEMS AND METHODS FOR PERFORMING ELECTROPHYSIOLOGY (EP) SIGNAL PROCESSING " was filed on October 28, 2020. The patent describes and claims systems and methods for filtering noise (e.g., a cardiac signal) during a quiet period. In particular, this patent involves filtering out harmonics and noise from an input cardiac signal.